Abbvie Inc ABBV

$264.34 -0.78 (-0.29%)

Valuation

Market cap
468,412,160,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.39
Forward PE
18.86
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
2,541,700
Avg volume
4,707,940
Day's range
$262.59 – $266.00
Shares out
1,766,793,000
Stochastic %K
56%
Beta
0.29
Analysts
Strong Sell
Price target
$277.87

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

dagster01 Sep 26, 2:02 AM
$BMY $VKTX $NVO $ABBV IMO, it is smart for BL to move on and let the suitors conpete for his attention. Thry need Viking now more than Viking needs them.
0 replies
biolover Sep 26, 1:51 AM
$BMY $VKTX BL will not sell. It is obvious now. He will partner for the right deal. And agree BMY as desperate as novo. $NVO holders - some clueless and trash VK not realizing VK is a gift from heaven to save their company. Although I honestly believe when it is heated and the offer is close to final .: BMY , $ABBV or even Lilly will not make it easy on novo and they may snatch the deal.
1 replies
StocktwitsNews Sep 26, 1:02 AM
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines $NVO $LLY $NVS $ABBV https://stocktwits.com/news/equity/markets/biotech-deal-week-lilly-novo-and-novartis-pay-up-for-platforms-not-pipelines/cZMXysORBOn
0 replies
quassarcapital Sep 25, 10:54 PM
$ABBV (AbbVie) gets FDA approval for tavapadon (brand name Juvmo), a once-daily pill for Parkinson's disease, with the drug acquired through AbbVie's 2023 purchase of Cerevel Therapeutics.
0 replies
jheerdink Sep 25, 5:30 PM
$ABBV https://vistapglobal.com/serina-therapeutics-advances-ser-252-in-advanced-parkinsons-disease-as-continuous-therapy-market-expands-abbv-ser/
0 replies
SanKish Sep 25, 3:38 PM
$ABBV $AZN $PROK $TMO $VRTX that will be wonderful and a great help for multiple stakeholders - patients (because dialysis is painful and weakens heart over time), govt (because it is costly and too many additional Medicare expenses ) and hopefully hospitals and insurance companies ( if they are really thinking of saving their resources for better patient care).
1 replies
maphere Sep 25, 2:26 PM
$RGNX Check out the slide deck: Per ChatGPT: At the pivotal sura-vec dose, 6/10 evaluable patients were ≥2-step DRSS improved at Year 3 with no vision-threatening event and ZERO additional DR injections. Of those 6: • 2 maintained ≥2-step improvement from Yr 1 • 3 went from 1-step → 2-step improvement • 1 went from no improvement → 2-step improvement All after a single in-office injection 3 years earlier. Small Phase 2 dataset, but that's a very interesting durability trajectory as $ABBV advances NAAVIGATE. The surprising finding is that several patients didn't merely maintain an early response—their DRSS category continued improving between Years 1 and 3 without rescue treatment. And given that we've been following sura-vec closely, Slide 9 is probably the single ALTITUDE slide I'd save. It tells the story considerably better than the PR does. https://www.regenxbio.com/science-innovation/publications/
0 replies
topstockalerts Sep 25, 2:00 AM
ADARx Pharmaceuticals priced its IPO of 26.25 million common shares at $17 per share, valuing the offering at approximately $446.3 million in gross proceeds before underwriting discounts, commissions and other expenses. The San Diego-based clinical-stage biotechnology company is expected to begin trading on the Nasdaq Global Select Market on Sept. 25 under the ticker ADRX, with the offering scheduled to close on Sept. 28. Underwriters also have a 30-day option to purchase up to 3.9375 million additional shares at the IPO price. Separately, AbbVie has agreed to purchase ADARx shares in a concurrent private placement at $17 per share, with the investment capped at $100 million. Combined gross proceeds from the IPO and private placement are expected to reach approximately $535.2 million, excluding any exercise of the underwriters’ option. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are serving as lead book-running managers, with LifeSci Capital as bookrunner. $MS $ABBV
0 replies